Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 10

525P - Immuno markers in newly glioblastoma patients underwent Stupp protocol after neurosurgery

Date

21 Oct 2023

Session

Poster session 10

Topics

Tumour Site

Central Nervous System Malignancies

Presenters

Lorena Gurrieri

Citation

Annals of Oncology (2023) 34 (suppl_2): S391-S409. 10.1016/S0923-7534(23)01934-8

Authors

L. Gurrieri1, L. Mercatali2, T. Ibrahim3, V. Fausti1, M. Dall'Agata4, M.N. Riva1, N. Ranallo1, G. Pasini5, M. Tazzari1, F. Foca4, D. Bartolini6, L. Riccioni6, C. Cavatorta6, F. Morigi6, J. Bulgarelli1, C. Cocchi2, V. Ghini1, L. Tosatto7, L. Ridolfi1

Author affiliations

  • 1 Clinical And Experimental Oncology, Immunotherapy, Rare Cancers And Biological Resource Center, IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS, 47014 - Meldola/IT
  • 2 Preclinic And Osteoncology Unit, Bioscience Laboratory, IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS, 47014 - Meldola/IT
  • 3 Bone & Soft Tissue Sarcomas And Innovative Therapies Dept., IOR - Istituto Ortopedico Rizzoli - IRCCS, 40136 - Bologna/IT
  • 4 Unit Of Biostatistics And Clinical Trials, IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS, 47014 - Meldola/IT
  • 5 Department Of Medical Oncology, Infermi Hospital, 47900 - Rimini/IT
  • 6 Pathology Unit, M. Bufalini Hospital, 47521 - Cesena/IT
  • 7 Neurosurgery, M. Bufalini Hospital, 47521 - Cesena/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 525P

Background

Glioblastoma (GBM) is characterized by an “immune-deserted” tumor microenvironment (TME) consisting of tumor-associated macrophages (TAMs) and tumor infiltrating lymphocytes (TILs). We aimed to investigate the prognostic role of tumor tissue markers correlating with overall survival (OS) and progression-free survival (PFS).

Methods

By immunohistochemistry (IHC), we analyzed on 31 archival formalin-fixed paraffin embedded (FFPE) tissue specimens: CD3, CD4, CD8, CD20, CD45, CD68, CD163, CD66b and PDL-1. Expression values were classified according to density score from 0 to 4 (0=no expression; 1=1-25%; 2=26-50%, 3=51-74%; 4=75%-100%) in two areas: Vascular/perivascular (V) and diffuse in tumor parenchyma (D). Percentage of infiltrating immune system cell was calculated by the rate of absolute number of positive stained cells/total number of cells multiplied by 100.

Results

All tissues were negative for PDL1 and only two positive for CD20. We observed that CD68+ macrophage and CD66b+ neutrophils expressed in V showed a statistically significant prognostic role (p-value of 0.027 and 0.029 respectively) (Table). CD68-V showed a prognostic role for PFS (p-value 0.032), while CD66b-V expression did not. CD3, CD4, CD8, CD45 and CD163 were not associated with OS and PFS.

Table: 525P

Characteristics Univariable models OS Multivarible model OS Univariable models PFS Multivarible model PFS
HR (95%CI) P-value HR (95%CI) P-value HR (95%CI) P-value HR (95%CI) P-value
CD68V
0-1 1.00 - 1.00 - 1.00 - 1.00 -
2-4 0.42 (0.19-0.91) 0.027 0.46 (0.21-0.99) 0.049 0.41 (0.18-0.92) 0.032 0.45 (0.20-1.01) 0.054
CD66bV
0-1 1.00 - 1.00 - 1.00 - 1.00 -
2-4 0.38 (0.16-0.90) 0.029 0.41 (0.17-0.98) 0.046 0.45 (0.17-1.12) 0.087 0.49 (0.19-1.24) 0.136

Conclusions

Despite having a smaller cohort of tissues, we showed a different expression of immune markers. In particular, CD68-V was associated with a significant positive impact on both OS and PFS. This relation could be partially explained because TAM do not raise only from peripheral blood, but also from resident microglia. Moreover, we observed high density of CD66b+ cells in V related to OS probably for growth factors overproducted by tumor cells with their recruitment from blood. Further studies are needed in large series to explore the prognostic role of selected TME immune molecules to develop therapeutic strategies that aim to hit different components of GBM.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

IRST and Area Vasta Romagna Ethics Committee.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.